IgGenix
Mattias Westman is co-founder of Prosperity Capital Management (PCM), founded in 1996. He is currently based in Milan, Italy.
Previously, Mattias has served as a board member for corporations including Immunometrix, a company focused on non-invasive delivery of large molecules through the skin via patch, which was subsequently sold to CareDx (NASDAQ: CDNA). He also served on the board of Lineage Biosciences, a biotech researching cell-based therapy for a variety of conditions, which was sold to AbCellera (NASDAQ: ABCL). Mattias currently sits on the board of a biotech utilizing epigenomics for early stage, non-invasive cancer screenings – Bluestar Genomics. He also played an active role at a Swedish investment bank, HQ Bank. Prior to founding PCM, Mattias was director of Alfred Berg, a Swedish investment bank.
He holds a master’s degree from the Stockholm School of Economics.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
IgGenix
IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. They work on translating research discoveries into transformative therapies for individuals suffering from allergies.